The Natural History Of Initially Untreated Low Grade Non-hodgkins Lymphomas
New England Journal of Medicine 311(23): Dec 6 1984; 1471-1475
View Original Source →Abstract
The spontaneous regression (SR) of tumor has been noted in a variety of neoplastic conditions. In non-Hodgkin’s lymphoma, this phenomenon has been reported in indolent histologic subtypes, with a frequency of 10-20% in selected series. Investigators evaluating new therapies for lymphomas with a favorable histology need to be cognizant of SR’s impact. Mechanisms which have been proposed to explain SR have included the role of contemporaneous bacterial or viral infection, as well as an augmented host immune response which is able to mediate tumor regression via humoral and cellular effector mechanisms. The ability to recapture immunoregulatory control is aptly illustrated by lymphomas developing after organ transplantation where reduction of immunosuppression has, on occasion, resulted in tumor regression. The importance of immune regulation of B-cell lymphoma is also suggested by the tumor’s responses to immunotherapy and interferons in-vivo and by the biologic and pathologic characteristic of indolent lymphomas being analogous, in many respects, to benign neoplasms. Indolent lymphomas which differ from aggressive lymphomas in their clinical and biological behavior may be more responsive to these host immunoregulatory influences. Review of clinical experience as well as proposed mechanisms of spontaneous regression in non-Hodgkin’s lymphoma are explored in this report.
Case Details
Clinical Characteristics
Advanced disease was initially managed without therapy, histologic transformation to an intermediate-grade or high-grade lymphoma occurred both before and after primary therapy
Remission Characteristics
Spontaneous regression of disease was observed in 19 cases (23%), including 30% of patients with nodular, poorly differentiated lymphocytic lymphoma. The median time from diagnosis to spontaneous regression was eight months. Regressions were complete in 6 patients and incomplete in the remaining 13
Treatment & Mechanisms
Proposed Remission Mechanisms
Disease regression after viral infection, a possible interferon effect
Non-Clinical Treatment
Withholding treatment until there is evidence of disease progression
Additional Notes
Actuarial survival was 82% at 5 years and 73% at 10 years. The median time until therapy was required was three years. The actuarial risk of transformation among the initially untreated patients was similar to that in a group of patients treated at this institution immediately after diagnosis. Neither the time to histologic transformation nor the incidence of transformation was influenced by when therapy was started. One of the complete regressions occurred after a clinical viral illness.